Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring or in-licensing innovative branded pharmaceuticals, oncology treatments and medical devices. Through partnerships and targeted acquisitions, the company brings products to market in regions where unmet medical needs exist, collaborating with global research and development organizations to expand patient access to novel therapies. Its business model centers on identifying late-stage compounds and approved products with established safety profiles, then assuming responsibility for regulatory approvals, marketing and distribution.
The company’s product portfolio spans multiple therapeutic areas, including oncology, ophthalmology, cardiometabolic disorders, infectious diseases and pain management. In oncology, Knight offers targeted therapies and supportive care treatments designed to improve patient outcomes and quality of life. Its portfolio also includes ophthalmic solutions for retinal conditions, chronic disease medications for diabetes and hypertension, as well as antibiotics and antivirals for emerging infectious threats.
Knight Therapeutics leverages a diversified geographic footprint, with core markets in Canada and across Latin America, including Mexico, Colombia, Chile, Peru and Brazil, where it operates through a network of subsidiaries and distributors. The company also maintains a European distribution platform via its acquisition of Produlab Pharma, which enables access to markets in Germany, Austria and other countries in the European Economic Area. This international reach allows Knight to tailor its commercialization strategies to local healthcare systems and regulatory environments.
Founded in 2011 as a spin-off from Paladin Labs, Knight Therapeutics has grown through disciplined deal-making and a strategic focus on late-stage product opportunities. The company is led by President and Chief Executive Officer Jonathan Ross Goodman, supported by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial operations. Under their guidance, Knight continues to expand its pipeline of in-licensed products and pursue strategic collaborations that align with its mission of improving patient access to essential therapies.
AI Generated. May Contain Errors.
Free KHTRF Stock Alerts